Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Naproxen Label Shows Limitations Of Class Effect Thinking – Harvard’s Avorn

Sep 12 2005

• By The Tan Sheet

Related Content

NSAID Labeling Revisions Revised By FDA; Compliance Date Extended

Jul 25 2005

Additional Topics

OTC Drugs Consumer

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window